AbbVie reports Phase 2a data showing ABBV‑466 achieves higher remission rates in Crohn’s disease
AbbVie announced results from the ongoing Phase 2a TARGET‑CD study of its investigational dual‑targeting therapy ABBV‑466 in moderate‑to‑severe Crohn’s disease. In 300 patients, 30.2% achieved endoscopic remission at Week 12 and 40.5% at Week 24, outperforming the anti‑IL‑23 and anti‑α4β7 monotherapies. Safety was comparable, with serious adverse events reported in 10.4% of ABBV‑466 patients. The data will be presented as a late‑breaking abstract at the 2026 United European Gastroenterology Week Congress.
Why it matters
The company says the results support its strategy to develop next‑generation IBD therapies and could expand its pipeline if the drug advances to later‑stage trials. No revenue or guidance impact is disclosed, so the immediate effect is limited to potential future market opportunity.
Key facts
- 1The TARGET‑CD study enrolled 300 patients (94 on risankizumab, 100 on trosunilimab, 106 on ABBV‑466). news.abbvie.com
- 2At Week 12, 30.2% of ABBV‑466 patients achieved endoscopic remission, versus 21.3% on risankizumab and 18.0% on trosunilimab. news.abbvie.com
- 3At Week 24, remission rose to 40.5% for ABBV‑466, compared with 22.4% for risankizumab and 20.0% for trosunilimab. news.abbvie.com
- 4Serious adverse events occurred in 10.4% of ABBV‑466 patients, similar to 9.6% for risankizumab and 9.0% for trosunilimab. news.abbvie.com
- 5The findings will be presented as a late‑breaking abstract at the 2026 United European Gastroenterology Week Congress in Barcelona, October 17‑20. news.abbvie.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.